It is often said that some government regulator or another is in the pocket of industry.
In the case of the Food and Drug Administration, it’s a fact prescribed by federal law.
To understand how, consider the legally mandated process that has been playing out over the past year between regulators at the FDA and representatives of the drug industry they oversee.
From September 2015 to January 2016, teams of FDA officials held 70 meetings with drug company executives and lobbyists to set goals that could have far-reaching consequences for the pharmaceutical industry, the FDA, and anyone who uses or pays for prescription drugs.
At issue: How the Food and Drug Administration should go about approving new drugs.
Read the full article here.